FDI-6

FDI-6 is a **small molecule inhibitor** that directly targets the transcription factor **FOXM1 (Forkhead box protein M1)**. By binding directly to FOXM1’s DNA-binding domain, FDI-6 prevents FOXM1 from attaching to its genomic targets, thereby downregulating the expression of FOXM1 and its downstream oncogenic targets such as Cyclin B1, Slug, and Snail. This selective inhibition leads to suppression of cancer cell proliferation, migration, invasion, and induction of apoptosis, particularly in cell lines with high FOXM1 expression. FDI-6 has also been shown to modulate angiogenesis by interfering with VEGF-B expression and exhibiting a strong interaction with the VEGFR1 (vascular endothelial growth factor receptor 1) protein, implicating additional anti-angiogenic activity. It has demonstrated synergy with other chemotherapeutics (e.g., doxorubicin) and sensitizes cancer cells to PARP inhibitors (e.g., olaparib). Currently, FDI-6 is used as a research tool and not for human clinical therapy[1][2][3][4][5][6].

Other names

Forkhead domain inhibitor-6